CapitolRadar tracks every publicly disclosed MRK trade by US congress members and corporate insiders: 115 disclosed trades (54 buys, 61 sells) by 9 tracked traders, from 2020-02-18 to 2026-09-24. Updated daily from official filings.
Want a ping when Congress buys MRK? Free email alerts on notable disclosed trades — plus a $100,000 fantasy portfolio to play along against three AI traders. Join free
Merck & Co., Inc. (MRK) — Healthcare · Drug Manufacturers - General, market cap about $358.6B.
CapitolRadar analysis
112 trades split nearly evenly between purchases and sales
MRK has 112 tracked trades from February 18, 2020 through August 19, 2026, involving nine distinct traders. The total comprises 54 buys and 58 sells, so sales exceed purchases by four. That is a close overall split rather than a strongly one-sided pattern. The dataset covers congressional and disclosed trading activity in Merck & Co., Inc., a Healthcare company in the Drug Manufacturers - General industry.
The eight listed buyers account for 53 of the 54 purchases. Ro Khanna recorded 25 buys, Lois Frankel 11, and Michael McCaul seven. Together, those three generated 43 purchases, or about 80% of all tracked buys. The remaining listed buyers recorded nine purchases combined: Jared Moskowitz four, Marjorie Taylor Greene three, and Maria Elvira Salazar, Josh Gottheimer, and Diana Harshbarger one each. This concentration means the buy count reflects a small number of repeat traders rather than broad participation.
21 recent quarterly trades produced 11 buys and 10 sells
Across the eight reported quarters from 2024 Q2 through 2026 Q3, MRK had 21 trades: 11 buys and 10 sells. The busiest listed quarter was 2025 Q2, with five trades and four buys. By contrast, 2025 Q1 had two trades and no buys, while 2024 Q2 had one trade and no buys. The latest listed quarter, 2026 Q3, contains two trades, both purchases. These quarterly samples are small, so changes in direction can be driven by only one or two disclosures.
3 buyers also appeared in PANW and META
Among MRK buyers, three also bought PANW and three also bought META. Two buyers each also purchased AJG, DELL, TJX, and WDAY. These overlaps describe disclosed trading only and do not establish a common rationale. Congressional disclosures can be filed up to 45 days after a transaction, so reported activity may lag the underlying trade date. Disclosed dollar amounts are generally reported as ranges, making any value-based totals estimates; no transaction-value figures are provided here.
Analysis written from the tracked record on 2026-09-13; it is refreshed whenever the underlying numbers change.
Activity by quarter
| Quarter | Disclosed trades | Buys | Sells |
|---|---|---|---|
| 2026 Q3 | 5 | 2 | 3 |
| 2026 Q1 | 3 | 1 | 2 |
| 2025 Q3 | 2 | 1 | 1 |
| 2025 Q2 | 5 | 4 | 1 |
| 2025 Q1 | 2 | 0 | 2 |
| 2024 Q4 | 4 | 2 | 2 |
| 2024 Q3 | 2 | 1 | 1 |
| 2024 Q2 | 1 | 0 | 1 |
Who is buying MRK?
| Trader | Disclosed buys | Last buy | Grade |
|---|---|---|---|
| Ro Khanna | 25 | 2026-08-07 | — |
| Lois Frankel | 11 | 2021-12-03 | — |
| Michael McCaul | 7 | 2025-05-19 | — |
| Jared Moskowitz | 4 | 2024-11-08 | — |
| Marjorie Taylor Greene | 3 | 2025-08-28 | — |
| Maria Elvira Salazar | 1 | 2026-08-19 | — |
| Josh Gottheimer | 1 | 2026-02-04 | — |
| Diana Harshbarger | 1 | 2022-06-21 | — |
Disclosed trades in MRK
| Date | Who | Type | Amount | 30d vs SPY |
|---|---|---|---|---|
| 2026-09-24 | Maria Elvira Salazar | sell | $1,001 - $15,000 | — |
| 2026-09-04 | Ro Khanna | sell | $1,001 - $15,000 | — |
| 2026-08-28 | Michael McCaul | sell | $50,001 - $100,000 | — |
| 2026-08-19 | Maria Elvira Salazar | buy | $15,001 - $50,000 | — |
| 2026-08-07 | Ro Khanna | buy | $15,001 - $50,000 | — |
| 2026-02-04 | Josh Gottheimer | buy | $1,001 - $15,000 | — |
| 2026-01-29 | Ro Khanna | sell | $15,001 - $50,000 | — |
| 2026-01-13 | Michael McCaul | sell | $15,001 - $50,000 | — |
| 2025-09-29 | Ro Khanna | sell | $1,001 - $15,000 | — |
| 2025-08-28 | Marjorie Taylor Greene | buy | $1,001 - $15,000 | — |
| 2025-05-19 | Michael McCaul | buy | $50,001 - $100,000 | — |
| 2025-05-09 | Ro Khanna | sell | $1,001 - $15,000 | — |
| 2025-05-05 | Marjorie Taylor Greene | buy | $1,001 - $15,000 | — |
| 2025-04-09 | Marjorie Taylor Greene | buy | $1,001 - $15,000 | — |
| 2025-04-02 | Michael McCaul | buy | $100,001 - $250,000 | — |
| 2025-01-27 | Josh Gottheimer | sell | $15,001 - $50,000 | — |
| 2025-01-15 | Jared Moskowitz | sell | $1,001 - $15,000 | — |
| 2024-11-08 | Jared Moskowitz | buy | $1,001 - $15,000 | — |
| 2024-10-14 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2024-10-09 | Michael McCaul | sell | $1,001 - $15,000 | — |
These buyers also bought
Other stocks the tracked buyers of MRK disclosed buying in the last six months: MSFT (3) · META (3) · MNST (2) · SNDK (2) · TSM (2) · ACN (2).
About Merck & Co., Inc.
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of v…
Frequently asked questions
Which politicians bought MRK most?
Ro Khanna leads with 25 disclosed buys, followed by Lois Frankel.
How current is this page?
It re-renders from the tracked record on every view and new filings are ingested daily — but STOCK Act disclosures can lag the trade by up to 45 days, so the most recent weeks are always incomplete.
Get alerts when trades like these are disclosed. Free account: fantasy portfolio + email alerts. Premium: a 6-hour head start on every signal.
CapitolRadar tracks publicly disclosed trades (STOCK Act filings and SEC Form 4). Disclosures can lag the trade by up to 45 days. Backtests measure past disclosed buys against the S&P 500 and do not predict future results. Everything on this page is impersonal information for your own research — not investment advice.